Acorda Therapeutics, Inc. (NASDAQ:ACOR)

CAPS Rating: 2 out of 5

A commercial-stage biopharmaceutical company dedicated to the identification, development & commercialization of novel therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the CNS.

Recs

0
Player Avatar TMFBiologyFool (98.25) Submitted: 7/1/2009 5:35:48 PM : Outperform Start Price: $24.90 ACOR Score: -55.13

FDA approval seems likely.

Featured Broker Partners


Advertisement